PB Ratio: 0.63

Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.

Is the P/B ratio high or low?

The P/B ratio of 0.63 is 29% below its estimated 1-year average of 0.89, near the low end of its estimated 1-year range (0.63–1.16).

As of 2026-10-06T19:43:09.880Z.

RNA PB Ratio Metrics

P/B vs. estimated history

At 0.63, P/B is below its estimated 1-year median — higher than 3% of readings in its estimated 1-year history.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

Book Value Analysis

PB Ratio Formula & Definition

PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)

The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PB Ratio FAQ

What is the P/B ratio for Atrium Therapeutics, Inc. (RNA)?

The P/B ratio for RNA stock is 0.63.

Is Atrium Therapeutics, Inc.'s P/B ratio high or low?

The P/B ratio of 0.63 is 29% below its estimated 1-year average of 0.89, near the low end of its estimated 1-year range (0.63–1.16).

Related Metrics